Key result
Epicardial fragmentation mapping and ablation yields 0% VF recurrence at 6 months in Brugada syndrome.
Why the study?
Brugada syndrome carries a high risk of ventricular fibrillation despite ICD therapy, and optimal procedural endpoints for epicardial substrate ablation remain unclear.
Does epicardial high-density substrate ablation guided by fragmentation mapping eliminate arrhythmogenic substrate and normalize ECG patterns in patients with Brugada syndrome?
Case Report (n=3)
Does epicardial high-density substrate ablation guided by fragmentation mapping eliminate arrhythmogenic substrate and normalize ECG patterns in patients with Brugada syndrome?
High-density epicardial fragmentation mapping is feasible and may serve as an objective procedural endpoint for substrate ablation in Brugada syndrome.
No VF recurrence or ICD therapies after ablation in 3 Brugada cases; hypothesis-generating and leaves open need for larger prospective trials.
Background: Brugada syndrome (BrS) carries a high risk of ventricular fibrillation (VF) despite protective therapy with implantable cardioverter-defibrillators (ICDs). Catheter ablation targeting epicardial substrate in the right ventricular outflow tract (RVOT) has emerged as a promising adjunctive strategy; however, optimal procedural endpoints remain unclear. Objective: To present a case series of three BrS patients who underwent high-density (HD) epicardial substrate ablation assisted by electrogram fragmentation mapping, and to review contemporary evidence on Brugada substrate ablation. Methods: Three symptomatic BrS patients underwent epicardial HD mapping using the EnSite X three-dimensional mapping system and Advisor HD Grid catheter. A dedicated fractionation mapping algorithm was used to identify regions of abnormal electrograms. All spontaneous fractionated or late potentials were ablated until the fragmentation map showed no residual abnormal points. Results: In our three cases, HD mapping localized clusters of low-voltage, fractionated electrograms in the RVOT epicardium, which were successfully eliminated with epicardial radiofrequency ablation. Complete substrate removal resulted in normalization of the Brugada electrocardiographic pattern in all patients and rendered VF non-inducible. Over 6 months of follow-up, no VF recurrence was noted and no ICD therapies were delivered. No major procedural complications were observed. Post-ablation voltage maps remained patchy (reflecting residual scar tissue); however, the fragmentation maps became uniformly clean, supporting their utility as an objective endpoint. Conclusions: This case series demonstrates the feasibility of using fragmentation mapping as an intra-procedural guide and endpoint for Brugada ablation in the absence of drug challenge. Fragmentation mapping appeared to reproducibly confirm complete substrate elimination.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) conducted a case report in Brugada syndrome (n=3). High-density epicardial substrate ablation assisted by electrogram fragmentation mapping was evaluated on Ventricular fibrillation (VF) recurrence. High-density epicardial fragmentation mapping and ablation normalized the Brugada ECG pattern and resulted in 0% ventricular fibrillation recurrence in 3 patients over 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: